Malaysian Biotech Expects Huge Boost With Tamiflu Generic Contract
This article was originally published in PharmAsia News
Executive Summary
Malaysia's CCM Duopharma Biotech expects to see a huge increase in earnings this year due to a government contract to produce a generic version of Roche's Tamiflu (oseltamivir)